OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

Acinetobacter baumannii complex (ABC) causes severe infections such as pneumonia and septic shock, yet therapeutic options—particularly for carbapenem‑resistant strains (CRAB)—remain scarce amid rising antimicrobial resistance. This

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, a Novel Antimicrobial Peptide Targeting Acinetobacter

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6, a Novel Antimicrobial Peptide for Acinetobacter baumannii (AB), Conducted in Healthy Volunteers Access

OMNIX MEDICAL: UN PAPILLON CONTRE ACINETOBACTER BAUMANNII

More To Explore

REVIEW: Acinetobacter baumannii Complex Infections: New Treatment Options in the Antibiotic Pipeline

A Phase I First-in-Human Study To Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6

Safety and Pharmacokinetic Results from the First-in-Human Study with Intravenously Administered OMN6 (A Poster)

Contact Us

Reach US